Huiying Medical is an AI-powered high-tech company offering assistive solutions for medical image screening and diagnosis. With the technologies of artificial intelligence, cloud computing and big data, Huiying Medical is committed to create the intelligent, digital and mobile medical images. Huiying Medical’s cloud-based, deep-learning applications range from vascular and lung disease to breast cancer diagnosis. Huiying has obtained 31 intellectual property rights, including 7 utility patents, 22 software copyrights, 3 appearance design patents.
Huiying Medical has collaborated with nearly 1,000 top Chinese hospitals on scientific research topics and clinical practice, including 500 tertiary hospitals such as Chinese PLA General Hospital, Beijing Friendship Hospital and Peking Union Medical College Hospital. In 2018, the cooperation map has been expanded to Japan, the United Kingdom, France, Canada and other countries to accelerate the process of internationalization.
Headquartered in Beijing, Huiying Medical has offices in Silicon Valley U.S., Hong Kong, Suzhou and Guangzhou. The core team of Huiying Medical has more than 10 years’ experience on medical imaging AI.The Chief Scientist, Professor Xing Lei, is the Head of the Medical Physics Department at Stanford. He is one of the most renowned Chinese scientists to focus on medical imaging. Huiying Medical has more than 200 employees, among which around 80 members have obtained a doctor's degree or had overseas experience.
Huiying Medical’s cloud-based, deep-learning applications range from vascular disease, Tuberculosis, and lung disease to breast cancer diagnosis.
Huiying Medical developed the "Artificial Intelligence Breast Cancer Full Cycle Health Management System" to provide a reliable artificial intelligence solution covering from screening, diagnosis to follow-up. With the continuous breakthrough of artificial intelligence technology and the gradual integration with the healthcare field, it has become possible to apply AI to the prevention and treatment of breast cancer. Through AI technology, it will reduce breast cancer mortality and increase breast conservation rate.
The application can be mainly divided into three stages:
artificial intelligence participates in the breast images interpretation.
artificial intelligence provides an accurate basis for clinical decision making with the support of Radiomics (Scientific research platform).
artificial intelligence participates in analyzing follow-up data to enable postoperative evaluation and prediction.
HuiyiHuiying and Intel jointly launched the "Artificial Intelligence Breast Cancer Full Cycle Health Management System" to help screening and diagnosis through artificial intelligence technology.